As always, it was a pleasure to meet our Expert Faculty Member, Dr Tobias Boettler (University of Freiburg, Freiburg, Germany) following the EASL ILC 2021 conference. This time we discuss his highlights from the recent meeting in the field of hepatitis.
- Could you give us an overview of what we learned about the antiviral drug VIR-2218 and its promise in the treatment of patients with hepatitis B at the meeting? (0:16)
- Results from the MYR301 phase 3 study were also presented. What do you feel they have taught us about the clinical utility of bulevirtide in the treatment of patients with chronic hepatitis D? (1:23)
- COVID-19 was clearly one of the key topics this year. What did we learn about the impact of the pandemic on efforts to eliminate Hepatitis C? (2:56)
- Could you summarise your highlights from the various viral hepatitis sessions presented at the conference? (4:33)
Disclosures: Dr Tobias Boettler has served as a consultant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June
Share this Video
Related Videos In Viral Infections
Lulu Nair, IAS 2021: The Health Burden of HIV among Young Women in Africa
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the the health burden of HIV among young women and adolescent girls in Africa, and the need for pre-exposure prophylaxis. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in […]
Lulu Nair, IAS 2021: Interim results from the REACH study
touchINFECTIOUSDISEASES were pleased to meet with Lulu (Gonasagrie) Nair (Stellenbosch University, Stellenbosch, South Africa) to discuss the interim results from the REACH study. The abstract entitled: ‘Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study’ was presented at IAS 2021 – […]
Heiner Wedemeyer, EASL ILC 2021: Bulevirtide Phase 3 Hepatitis D Study
It was a pleasure to be able to speak to Prof. Heiner Wedemeyer (Hannover Medical School, Hannover, Germany) about the interim results from the phase 3 MYR301 study investigating bulevirtide monotherapy in patients with chronic hepatitis D. His abstract entitled ‘Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!